Publications by the researcher in collaboration with José Ramón González Juanatey (26)

2025

  1. Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial

    Circulation: Cardiovascular Quality and Outcomes, Vol. 18, Núm. 3, pp. e010849

2024

  1. 4020-7. Efecto a corto y largo plazo de dapaglifozina sobre el remodelado ventricular en pacientes con insuficiencia cardiaca crónica

    SEC 2024 - El Congreso de la Salud Cardiovascular

  2. 5005-9. Efecto de dapaglifozina sobre la evolución de parámetros ecocardiográficos del ventrículo izquierdo según el fenotipo de fracción de eyección en pacientes con insuficiencia cardiaca crónica

    SEC 2024 - El Congreso de la Salud Cardiovascular

  3. 6053-345. Parámetros de geometría y de función auricular en pacientes con insuficiencia cardiaca crónica estable y su respuesta al tratamiento con dapagliflozina

    SEC 2024 - El Congreso de la Salud Cardiovascular

  4. 6104-2. Beneficio de la colchicina en insuficiencia cardiaca aguda: diseño y características basales de un ensayo clínico aleatorizado, doble ciego, controlado con placebo (COLICA)

    SEC 2024 - El Congreso de la Salud Cardiovascular

  5. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure, Vol. 26, Núm. 9, pp. 1999-2007

  6. Colchicine in acutely decompensated heart failure: the COLICA trial

    European Heart Journal, Vol. 45, Núm. 45, pp. 4826-4836

  7. Rationale and design of a randomized double-blind trial to study the benefit of colchicine in patients with acutely decompensated heart failure: COLICA trial.

    ESC Congress - Heart Failure 2024

2023

  1. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  3. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  4. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  2. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1

  3. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  4. Environmental factors like air pollution: not to be forgotten in the 2021 ESC guidelines on heart failure. Response

    Revista Espanola de Cardiologia

  5. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

  6. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 6

  7. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12